To observe the clinical efficacy and side effects of morclobemide and doxepin in the treatment of depression. The author, randomly treated 66 depressed patients with morclobemide and doxepin in 33 cases each. The efficacy of the drugs was evaluated by HAMD, HAMA scale before and after treatment at weeks 1,2,3,4,6 and CGI-SI before and after treatment, and the side effects were evaluated by TESS scale, respectively. The results showed that there were significant differences in HAMD, HAMA, and CGI-SI subtraction scores before and after treatment between morclobemide and doxepin, but the differences were not significant in either group. The efficacy of moriclofenamide was good, and the incidence of side effects was low and mild. Conclusion, moriclofenamide not only has significant antidepressant efficacy, but also has good anxiolytic effect, with mild and safe side effects. Moriclofenamide is a novel reversible and selective MOAI, which achieves therapeutic effects mainly by selectively inhibiting MAO-A activity, reducing the degradation of monoamine transmitters 5-HT, NE and DA, and increasing the level of effective transmitters in the synaptic gap. It has been shown to be equally effective in mono- and biphasic, agonistic and delayed, endogenous and exogenous depressions and their various subtypes. The most significant improvement was observed in psychomotor retardation and affective depressive conditions. It has been used as a first-line antidepressant because of its low side effects and broad spectrum of administration, and it has also shown good results in anxiety disorders. Discussion: There is also a lot of domestic experience with the application of moriclofenamide. In this study, through a controlled study of 33 cases each of morclobemide and doxepin, the results showed a significant decrease in HAMD, HGI-SI scores in both groups after 6 weeks of treatment, but there was no significant comparison of the reduced scores in the two groups, which is consistent with domestic reports. It was found that moriclofenamide has a good anxiolytic effect as well as a definite antidepressant effect. The total effective rate of 96.96% was slightly higher than that of 93.93% for doxepin, but the difference between the two groups was not significant. Many literature reported that the adverse effects of moclobemide are mild, especially cardiovascular and anticholinergic effects are small. The present results showed that the main adverse effects of moriclofenamide were sleep disturbance, nausea, dizziness, and agitation. The incidence of anticholinergic side effects, such as dry mouth, constipation, blurred vision, difficulty urinating, and palpitations, was significantly higher with doxepin than with morclobemide. The incidence of ECG abnormalities was significantly lower in the morclobemide group than in the doxepin group. No strict dietary control was observed in the morclobemide group during the dosing period, and no effect on liver and kidney function was found. It is suggested that moriclofenamide not only has positive antidepressant effect, but also has significant anxiolytic effect, mild adverse effects and high safety. In order to observe the clinical efficacy and side effects of morclobemide and doxepin in the treatment of depression. The author, randomly treated 66 cases of depression with morclobemide and doxepin in 33 cases each. The efficacy of the drugs was evaluated by HAMD, HAMA scale before and after treatment at weeks 1,2,3,4,6 and CGI-SI before and after treatment, and the side effects were evaluated by TESS scale, respectively. The results showed that there were significant differences in HAMD, HAMA, and CGI-SI subtraction scores before and after treatment between morclobemide and doxepin, but the differences were not significant in either group. The efficacy of moriclofenamide was good, and the incidence of side effects was low and mild. Conclusion, moriclofenamide not only has significant antidepressant efficacy, but also has good anxiolytic effect, with mild and safe side effects. Moriclofenamide is a novel reversible and selective MOAI, which achieves therapeutic effects mainly by selectively inhibiting MAO-A activity, reducing the degradation of monoamine transmitters 5-HT, NE and DA, and increasing the level of effective transmitters in the synaptic gap. It has been shown to be equally effective in mono- and biphasic, agonistic and delayed, endogenous and exogenous depressions and their various subtypes. The most significant improvement was observed in psychomotor retardation and affective depressive conditions. It has been used as a first-line antidepressant because of its low side effects and broad spectrum of administration, and it has also shown good results in anxiety disorders. Discussion: There is also a lot of domestic experience with the application of moriclofenamide. In this study, through a controlled study of 33 cases each of morclobemide and doxepin, the results showed a significant decrease in HAMD, HGI-SI scores in both groups after 6 weeks of treatment, but there was no significant comparison of the reduced scores in the two groups, which is consistent with domestic reports. It was found that moriclofenamide has a good anxiolytic effect as well as a definite antidepressant effect. The total effective rate of 96.96% was slightly higher than that of 93.93% for doxepin, but the difference between the two groups was not significant. Many literature reported that the adverse effects of moclobemide are mild, especially cardiovascular and anticholinergic effects are small. The present results showed that the main adverse effects of moriclofenamide were sleep disturbance, nausea, dizziness, and agitation. The incidence of anticholinergic side effects, such as dry mouth, constipation, blurred vision, difficulty urinating, and palpitations, was significantly higher with doxepin than with morclobemide. The incidence of ECG abnormalities was significantly lower in the morclobemide group than in the doxepin group. No strict dietary control was observed in the morclobemide group during the dosing period, and no effect on liver and kidney function was found. It is suggested that moriclofenamide not only has positive antidepressant effect, but also has significant anxiolytic effect, mild adverse effects and high safety. In order to observe the clinical efficacy and side effects of morclobemide and doxepin in the treatment of depression. The author, randomly treated 66 cases of depression with morclobemide and doxepin in 33 cases each. The efficacy of the drugs was evaluated by HAMD, HAMA scale before and after treatment at weeks 1,2,3,4,6 and CGI-SI before and after treatment, and the side effects were evaluated by TESS scale, respectively. The results showed that there were significant differences in HAMD, HAMA, and CGI-SI subtraction scores before and after treatment between morclobemide and doxepin, but the differences were not significant in either group. The efficacy of moriclofenamide was good, and the incidence of side effects was low and mild. Conclusion, moriclofenamide not only has significant antidepressant efficacy, but also has good anxiolytic effect, with mild and safe side effects. Moriclofenamide is a novel reversible and selective MOAI, which achieves therapeutic effects mainly by selectively inhibiting MAO-A activity, reducing the degradation of monoamine transmitters 5-HT, NE and DA, and increasing the level of effective transmitters in the synaptic gap. It has been shown to be equally effective in mono- and biphasic, agonistic and delayed, endogenous and exogenous depressions and their various subtypes. The most significant improvement was observed in psychomotor retardation and affective depressive conditions. It has been used as a first-line antidepressant because of its low side effects and broad spectrum of administration, and it has also shown good results in anxiety disorders. Discussion: There is also a lot of domestic experience with the application of moriclofenamide. In this study, through a controlled study of 33 cases each of morclobemide and doxepin, the results showed a significant decrease in HAMD, HGI-SI scores in both groups after 6 weeks of treatment, but there was no significant comparison of the reduced scores in the two groups, which is consistent with domestic reports. It was found that moriclofenamide has a good anxiolytic effect as well as a definite antidepressant effect. The total effective rate of 96.96% was slightly higher than that of 93.93% for doxepin, but the difference between the two groups was not significant. Many literature reported that the adverse effects of moclobemide are mild, especially cardiovascular and anticholinergic effects are small. The present results showed that the main adverse effects of moriclofenamide were sleep disturbance, nausea, dizziness, and agitation. The incidence of anticholinergic side effects, such as dry mouth, constipation, blurred vision, difficulty urinating, and palpitations, was significantly higher with doxepin than with morclobemide. The incidence of ECG abnormalities was significantly lower in the morclobemide group than in the doxepin group. No strict dietary control was observed in the morclobemide group during the dosing period, and no effect on liver and kidney function was found. It is suggested that morclobemide not only has positive antidepressant effect, but also has significant anxiolytic effect, mild adverse effects and high safety.